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The art and science of anticoagulation have never gotten more complicated 
than it has now. Newer anticoagulants have entered the market and have pro-
vided more options to the patients and healthcare professionals. This chapter will 
review the basic physiology of hemostasis, pharmacology of the anticoagulants, 
and how these medications are used in the clinical setting. The mechanism of 
action, pharmacokinetics and pharmacodynamics, clinical evidence of use and 
clinical pearls, laboratory monitoring in clinical practice, and adverse effects will 
be examined individually for each drug considered. This chapter will serve as a 
review for the practicing clinician and a thorough introduction for the  
beginning reader.
Keywords: anticoagulants, warfarin, heparin, low molecular weight heparin, 
enoxaparin, dabigatran, rivaroxaban, apixaban, edoxaban
1. Introduction
Anticoagulants are the mainstay of treatment for stroke and systemic embo-
lism prevention in patients with atrial fibrillation (AF) or flutter. They can be 
used as well for prevention and treatment of venous thromboembolism (VTE) 
and treatment of thrombus formation in other places. This class of medications 
must be used carefully because using them incorrectly can lead to either ineffec-
tive prevention of clot formation or bleeding. It is vital for the clinician who uses 
any of these anticoagulants to have a basic understanding of their pharmacology 
and evidence of use.
2. The coagulation cascade
The coagulation system is composed of two separate pathways that convene on 
a single pathway. The two pathways are extrinsic pathway and intrinsic pathway. 
Injury to the endothelial system exposes tissue factor out in the bloodstream. The 
extrinsic pathway begins with factor VII. Circulating factor VII in the bloodstream 
will then get activated to factor VIIa when they come into contact with tissue factor. 
Factor VIIa then converts factors X and IX to factor Xa and IXa, respectively. The 
presence of factor IXa, together with factor VIIIa, work to produce more factor Xa. 
Factor Xa and factor Va then activate factor II (prothrombin) to factor IIa (throm-
bin). Factor IIa then converts fibrinogen to fibrin [1, 2].
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The result of this cascade is the production of fibrin molecules that bind to GPIIb/
IIIa receptors on platelets and hold them together to form a platelet plug. The extrinsic 
pathway is what protects humans when bleeding occurs involving trauma to the 
vasculature or when the blood comes in contact with extravascular tissues [1, 2].
The intrinsic pathway gets activated upon trauma to the blood or when the blood 
gets exposed to collagen found on damaged blood vessels. At the beginning of the 
intrinsic pathway activation, exposure of factor XII to collagen, for example, stimu-
lates a configurational change in factor XII to become factor XIIa. Together the help 
of high molecular weight kininogen and prekallikrein, factor XIIa enzymatically 
activates factor XI to XIa. Factor XIa in turn activates factor IX to IXa. Factor IXa 
then works with factor VIIIa to convert factor X to Xa. Factor Xa then converts fac-
tor II to factor IIa, which in turn activates fibrinogen to fibrin [1, 2].
The extrinsic pathway and intrinsic pathway converge as the common pathway 
when factor X gets converted to factor Xa [1, 2] (see Figure 1).
3. Basic and clinical pharmacology of the anticoagulants
3.1 Unfractionated heparin (UFH)
3.1.1 Mechanism of action
Unfractionated heparin is a long string of glycosaminoglycan molecules that 
can range from 3000 to 30,000 Daltons. UFH with its specific pentasaccharide 
sequence binds to antithrombin III and catalyzes its efficiency in inhibiting factor 
Xa and IIa in a ratio of 1: 1. However, not all heparin molecules given are active; only 
about a third of the heparin molecules in a solution contain the required pentasac-
charide sequence [1–3].
3.1.2 ADME
Heparin is not absorbed orally and is given either subcutaneously (SQ ) or intra-
venously (IV). Heparin is highly protein bound and is cleared in the bloodstream 
by endothelial cells and macrophages. The half-life of heparin increases as the dose 
increases; it can vary from 1 hour at a dose of 100 units/kg to 2.5 h for 400 units/kg 
to 5 h for 800 units/kg. In general, the clinical effect of IV UFH dissipates 4–6 hours 
after stopping the infusion [1–3].
Figure 1. 
Coagulation cascade showing the intrinsic, extrinsic, and common pathway. Reprint with permission from [30].
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3.1.3 Clinical use
UFH can be either given SQ or IV as mentioned above. However, SQ administra-
tion of UFH has erratic bioavailability. Hence, SQ is not a preferred route if a patient 
requires treatment dose of UFH. Clinical studies have also shown a higher rate of 
treatment failure rate with SQ compared to IV heparin [3, 4]. For VTE prophylaxis, 
SQ administration of UFH would suffice. The usual dose is 5000 units q8-12h [4].
Initial dosing of IV UFH depends on the indication. Besides VTE treatment, 
IV UFH can also be used for patients with acute coronary syndrome, as a bridg-
ing agent for patients with atrial fibrillation, mechanical valves, etc. The dose of 
IV UFH could be either a fixed dose or a weight-based dose. A study by Raschke 
et al. [3] compared fixed dose vs. weight-based dose of IV heparin in patients 
with venous and arterial thromboembolism. In that study, significantly more 
patients (97%) in the weight-based dosing group achieved an Activated Partial 
Thromboplastin Time (aPTT) > 1.5x the baseline within 24 hours vs. the fixed dose 
group (77%), leading the authors to conclude that weight-based dosing is superior 
to fixed dose IV heparin [3, 4]. The 2016 Guidance for the practical management of 
the heparin anticoagulants in the treatment of venous thromboembolism and the 
2012 American College of Chest Physicians (ACCP) Guidelines on Antithrombotic 
Therapy and Prevention of Thrombosis Supplement on Parenteral Anticoagulants 
list both fixed dose and weight-based dose for IV heparin [3].
3.1.4 Monitoring
There are two ways of monitoring the heparin activity in the body. These are the 
aPTT and Activated Clotting Time (ACT). The usual aPTT target for a therapeutic 
effect of heparin is 1.5–2x the baseline, which is equivalent to an anti-factor Xa 
activity of 0.3–0.7 units/ml [1, 3, 4]. The target aPTT varies based on what reagent 
is used to measure it. Thus, the clinician should check with the institution’s labora-
tory for the target aPTT for patients receiving IV heparin. When using IV UFH for 
treating heparin or for bridging purposes, the aPTT is used. Another lab test used 
to monitor heparin is the ACT. ACT is available as a point-of-care test and is used 
when patients are receiving high doses of heparin. ACT can be seen being used in 
instances such as during cardiopulmonary bypass surgery and percutaneous coro-
nary intervention. The target ACT varies based on the indication. ACT is reported 
in seconds and denotes how long it takes for the blood to clot.
3.1.5 Adverse effects
Patients on heparin also need close monitoring of platelet counts. 
Thrombocytopenia could be a consequence of heparin infusion and severe reaction 
called heparin-induced thrombocytopenia (HIT) may occur [1–5]. There are two 
kinds of heparin-induced thrombocytopenia: HIT type 1 and HIT type 2. HIT Type 
1, which may also be called heparin-associated thrombocytopenia, is a benign, 
transient drop in platelets counts usually within the first 2–4 days after initiation of 
heparin infusion. Platelet counts rarely go below 100,000 [3–6]. The mechanism 
behind HIT type 1 is unknown but may involve dilutional effect or decreased 
platelet production associated with the acute illness [6].
The other more serious reaction, which is HIT type 2, involves antibody for-
mation against heparin-platelet factor 4 complex. Heparin may bind to platelet 
factor-4 (PF 4), which is a cationic protein product of platelets that binds heparin 
and prevents heparin from binding with antithrombin. The heparin-PF4 complex 
is highly antigenic and induces the formation of IgG molecules against it. The IgG 
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molecule-heparin-PF 4 complex binds to platelets and activates it, further releas-
ing more PF4. The activated platelets with bound IgG-heparin-PF 4 complex also 
produce prothrombotic molecules that may cause thrombosis [3–6]. HIT type 2 can 
cause both arterial and venous thromboses, although venous thrombosis is more 
common. The activated platelets with bound IgG-heparin-PF 4 get removed from 
the body quickly, hence causing thrombocytopenia [6].
For the treatment of HIT, the American Society of Hematology 2018 guidelines 
for the management of venous thromboembolism: heparin-induced thrombocy-
topenia suggests use of non-heparin options such as argatroban (a direct thrombin 
inhibitor), fondaparinux (an ant-factor Xa inhibitor), or DOAC (specifically 
rivaroxaban due to most experience at a dose of 15 mg twice a day for 3 weeks if 
thrombosis is present, or 15 mg twice a day until the platelet counts have recovered 
to ≥150 × 109/L, then followed by 20 mg daily if there is an indication for continued 
anticoagulation) [7].
3.1.6 Reversibility
In the event of bleeding, heparin can be reversed with protamine sulfate. 
Protamine is a cationic protein from fish sperm that can bind to heparin (which 
is anionic) and neutralize heparin immediately [1]. 1 mg of protamine reverses 
approximately 100 units of heparin, with a maximum dose of 50 mg at a time. For 
patients who are receiving continuous IV heparin infusion, only the last 2–3 hours 
dose of heparin given needs to be taken into when calculating the dose for prot-
amine. For patients who received SQ heparin, protamine has to be given as a pro-
longed infusion. aPTT can be used to monitor the efficacy of protamine. One needs 
to be careful when giving protamine as protamine itself is prothrombotic [3, 5].
3.2 Low molecular weight heparin (LMWH)
There are various preparations of LMWH available in the market. Some exam-
ples are enoxaparin, dalteparin, tinzaparin, etc. The rest of the discussion in this 
section will focus on enoxaparin.
3.2.1 Mechanism of action
LMWH’s are shorter molecular version of UFH. They are only a third of the size 
of UFH. Same as UFH, LMWH bind to antithrombin and catalyzes its efficiency. 
But unlike UFH, the combination LMWH-antithrombin is only capable of deacti-
vating factor Xa and very little factor IIa [1, 3, 5].
3.2.2 ADME
Enoxaparin can be either given SQ or IV depending on the indication. It is 
predominantly cleared renally hence dose adjustment is needed in patients with 
renal impairment (when Cockcroft-Gault calculated creatinine clearance is <30 ml/
min). It has a half-life of 3–6 hours and reaches peak concentration 3–5 hours after 
SQ injection [1, 3–5].
3.2.3 Clinical use
Enoxaparin can be given as a once a day or twice daily dosing. Once daily dosing 
is not advisable in certain populations such as obese patients because the effect of 
enoxaparin would not last for 24 hours [4]. The dose varies based on the indication. 
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It can be used for VTE treatment and prophylaxis, arterial thromboses, bridging 
agent for patients with atrial fibrillation, mechanical valves, etc. It is easier to use 
in practice than IV heparin if full treatment dose is needed as there is no laboratory 
monitoring required.
3.2.4 Monitoring
The activity of LMWH is more predictable than UFH. Hence, monitoring is not 
needed when LMWH is given. However, its anticoagulation effects may be deter-
mined by checking the anti-factor Xa activity. Several guidelines including the 2016 
Guidelines for the practical management of the heparin anticoagulants in the treat-
ment of venous thromboembolism and the 2018 American Society of Hematology 
guidelines for the management of venous thromboembolism: optimal management 
of anticoagulation therapy do not suggest routing monitoring of anti-factor Xa 
activity due to uncertainties regarding its clinical utility and its cost-effectiveness 
[4, 8]. Additionally, there is currently no standardized method of adjusting the dose 
of enoxaparin based on anti-factor Xa activity [8], except for pediatric patients.
3.2.5 Adverse effects
As with any anticoagulants, bleeding is a major concern for patients receiving 
LMWH. Hematoma surrounding the injection site may also appear if patients rub 
on the injection site. In terms of major side effects, LMWH has a lower incidence of 
HIT type 2 compared to UFH. However, patients who have a history of HIT type 2 
should best avoid LMWH if antibodies are still present.
3.2.6 Reversibility
In cases of bleeding, enoxaparin may be partially reversed with protamine if 
it was given within 8 hours. Protamine can only reverse 65–70% of enoxaparin at 
most [5]. Protamine neutralizes anti factor IIa bound to the LMWH-antithrombin 
complex completely but only variably to factor Xa bound to the LMWH-
antithrombin complex [3, 5].
3.3 Warfarin
3.3.1 Mechanism of action
Warfarin has been used around since the early 1930s but it was not used clini-
cally until the 1950s. Warfarin is the oldest oral anticoagulant around. Warfarin 
inhibits vitamin K epoxide reductase (VKOR) that leads to the decrease in produc-
tion of factors II, VII, IX, and X. These factors depend on vitamin K for carbox-
ylation in order to become active. In addition to these four factors, vitamin K also 
decrease the production of protein C and S, which also depend on carboxylation to 
become active [5, 9, 10] (See Figure 2).
3.3.2 ADME
Warfarin is present as a racemic mixture of two enantiomers, S-warfarin and 
R-warfarin. S warfarin is about three times more potent than R-warfarin. The 
S-warfarin is metabolized by CYP 2C9, whereas R-warfarin is metabolized by CYP 1A1, 
1A2, and 3A4. Hence, any metabolic interactions involving these enzymes, especially 
2C9, would affect the clinical efficacy and safety of warfarin significantly [9, 10].
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Warfarin is readily absorbed and is almost 100% bioavailable. It has similar vol-
ume of distribution as albumin (0.11–0.18 L/kg) and is metabolized by the liver. It is 
a highly protein-bound drug (>98%) and has a half-life of 36–42 hours (R-warfarin 
45 hours, S-warfarin 29 hours). Advances in genetics have elucidated that polymor-
phisms in the gene that encode VKOR (VKORC1) and CYP2C9 enzyme dramati-
cally affect the dose requirement of a patient [9, 10]. Dose calculators based on the 
genetic polymorphisms of these two enzymes exist and some of them are available 
online. How accurate they are is still a question. It should be noted that each 
patient’s warfarin dose requirement does not rely only on genes. Genetics can only 
account for 30–50% of each patient’s dose requirement. Diet, medical condition, 
and drugs (including supplements) have a role to play as well in determining how 
much warfarin one needs.
3.3.3 Clinical use
Clinically, warfarin is used for various conditions such as prevention of stroke 
and systemic embolism in patients with atrial fibrillation or atrial flutter, treatment 
and prevention of venous thromboembolism, cerebral venous thrombosis, etc. 
Clinicians have the most experience with warfarin and warfarin has a wider range 
of indications than the direct-acting oral anticoagulants (DOACs).
There are several published sample algorithms on initiation and dosing of warfa-
rin. Several institutions also have in-house protocols and dose adjustment guidelines 
Figure 2. 
Vitamin K cycle showing where warfarin acts and the enzymes that metabolize each enantiomer. Reprint with 
permission from [16].
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for patients on warfarin. However, due to the multiple factors that can affect warfarin, 
the protocols may not be necessarily apt to follow. Picking the correct warfarin dose 
to start patients on and adjusting of warfarin doses subsequently is usually not as 
simple clinically. Choosing what dose to start patients on require a thorough review of 
that patient’s medical condition, weighing thrombotic risk against bleeding risk, and 
having considerable experience in managing patients on warfarin.
3.3.4 Monitoring
Upon initiation, it takes about 2–3 days usually to see an increase on the interna-
tional normalized ratio (INR) and about 5–7 days to see the full effect of warfarin 
on INR (corresponding approximately to the amount of time it takes for factor IIa 
to be depleted). A usual starting dose is 5 mg. Smaller doses such as 2 or 3 mg may 
be given in patients who are elderly or who are expected to have lesser dose require-
ments (e.g., CKD patients, patients with lighter body weight, presence of drugs that 
could raise the INR). Due to the delayed effect of warfarin, it may be overlapped 
with some faster-acting anticoagulants such as heparin, enoxaparin, or DOACs if 
immediate anticoagulation is needed.
INR is affected mainly by three factors, namely, drugs including natural supple-
ments, patient’s medical condition, and diet and lifestyle. These factors need to be 
considered when dosing a patient and when an explanation for a subtherapeutic or 
supratherapeutic INR is being sought.
3.3.5 Adverse effects
The most important adverse effect of warfarin is bleeding. Bleeding risk 
increases when the INR is >4. The risk of bleed is generally <3% annually if INR 
is kept between 2 and 3 [1]. If bleeding occurs and warfarin has to be reversed, 
patients should be given IV Vitamin K and Prothrombin Complex Concentrate 
(PCC). Fresh frozen plasma (FFP) may also be used as an alternative to PCC but 
it carries some disadvantages such as delayed administration due to thawing, and 
infusion of large volumes of fluid [9, 10].
Other notable adverse effects of warfarin include skin necrosis, which occurs 
3–8 days after initiation of warfarin [5]. Skin lesions appear due to thrombi in the 
capillaries and veins. They are usually found in areas rich with fatty tissue such 
as the breast, abdomen, and extremities. Skin lesion may occur in two types of 
patients. First is in patients treated with warfarin who have active HIT. Second is in 
patients who have protein S and/or C deficiency. The exact pathophysiology is not 
known but may be due to the abrupt drop in protein S and/or C before factors IIa, 
VIIa, IXa, and Xa drops sufficiently that cause the scale to tip over to the prothrom-
botic side. In such events, warfarin may be started slowly with concurrent heparin. 
Stop heparin when INR has reached the therapeutic range [10, 11].
Another adverse effect is purple toe syndrome that occurs 3–10 weeks after 
initiation of warfarin. The exact pathophysiology is not known but may be due 
to cholesterol deposits embolizing from the arterioles when the patient develops 
microbleeds in the atherosclerotic arterioles. The cholesterol emboli could occlude 
the arteries downstream. It can be reversed when it is discovered early and when 
warfarin is discontinued. Otherwise, it may lead to gangrene necessitating amputa-
tion [5, 11–13].
Other less serious adverse effects include osteoporosis, alopecia, etc. [5, 10]. 
Warfarin has also been associated with acute kidney injury termed warfarin-related 
nephropathy.
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3.4 Dabigatran
3.4.1 Mechanism of action
Dabigatran is a competitive direct thrombin (factor IIa) inhibitor. It binds to both 
free and clot-bound thrombin [1, 5, 10, 14]. This is in contrast to heparin which can 
only bind to free thrombin. As a result, fibrinogen cannot be converted to fibrin. 
Parenteral direct factor IIa inhibitors have been available in the market before the 
introduction of dabigatran. Some examples are argatroban, bivalirudin, etc.
3.4.2 ADME
Dabigatran has low oral bioavailability of only 3–7% and is a substrate of 
P-glycoprotein (P-gp). It comes as a prodrug called dabigatran etexilate that gets hydro-
lyzed to dabigatran. It reaches its peak concentration about 2 hours after ingestion. 
Dabigatran is 35% bound to protein and is highly (80%) renally excreted. Dabigatran is 
50–60% dialyzable, an important point to take note of especially in cases of toxicity. It 
has a half-life of 12–17 hours and is dosed twice a day [15, 16] (see Table 1).
3.4.3 Clinical use
Dabigatran was the first medication under the new class of medications called 
novel oral anticoagulants (NOAC) or Direct-acting Oral Anticoagulant (DOAC). 
Dabigatran is approved for stroke and systemic embolism (SSE) prevention for 
patients with non-valvular atrial fibrillation, treatment of VTE, and VTE prophy-
laxis post-hip replacement.
Dabigatran is available in three doses: 75, 110, and 150 mg. Some countries, in 
the United States, for example, only have 75 and 150 mg. As with the other NOACs, 
dabigatran can be given without the need for any monitoring of anticoagulation 
intensity. However, renal function must be monitored carefully as dabigatran is 
highly renally cleared (80% of the drug).
In terms of efficacy as compared to warfarin for SSE prevention, dabigatran 
110 mg has similar efficacy to warfarin titrated to an INR of 2–3. Dabigatran 
Table 1. 
Pharmacokinetic and pharmacodynamic properties of the different oral anticoagulants. Reprint with 
permission from [16].
9Pharmacological Review of Anticoagulants
DOI: http://dx.doi.org/10.5772/intechopen.88407
150 mg, on the other hand, is superior to warfarin titrated to an INR of 2–3. The 
superiority is mainly driven by a decrease in stroke events among patients taking 
dabigatran 150 mg. This is based on the RE-LY (Dabigatran versus Warfarin in 
Patients with Atrial Fibrillation) trial that led to the approval of dabigatran. In 
terms of bleeding risk, dabigatran 110 mg has lower overall major bleeding risk, 
similar gastrointestinal (GI) bleeding risk, and lower intracranial hemorrhage 
(ICH) compared to warfarin. With regards to dabigatran 150 mg vs. warfarin, 
dabigatran 150 mg has a similar overall bleeding risk, higher rates of GI bleed, and 
similar ICH risk compared to warfarin. These have to be taken into consideration 
when choosing which DOAC is more suitable for a patient [17] (see Table 2).
In terms of VTE treatment, dabigatran is not inferior to warfarin in terms of 
efficacy and safety based on the RE-COVER and RE-COVER II studies [17] (see 
Table 3). One caveat in its use for VTE treatment is that it requires a parenteral 
lead-in of at least 5 days with UFH or LMWH based on how it was carried out in the 
studies [19].
3.4.4 Monitoring
No pharmacodynamic monitoring is needed for any of the DOACs including 
dabigatran. Dabigatran has little effect on prothrombin time (PT) and INR. With 
regards to the activated partial thromboplastin time (aPTT), a normal aPTT does 
not exclude the presence of dabigatran. More sensitive tests for dabigatran are 
Thrombin Time (TT), Ecarin Clotting Time (ECT) and Diluted Thrombin Time 
(dTT) [20, 21] (see Table 1).
3.4.5 Adverse effects
Dabigatran, being a blood thinner, has bleeding as its main side effect. Careful 
consideration of the bleeding risk factors of the patients needs to be done prior to 
prescribing dabigatran 150 mg twice daily. History of prior GI bleeding, peptic 
ulcer disease, colonic angiodysplasia, and other pathologies that predispose a 
patient to GI bleeding are some practical issues that the prescriber needs to be 
mindful of. Dyspepsia, abdominal pain, and abdominal discomfort are other side 
effects that occurred more frequently compared to warfarin [5, 16]. The RE-LY trial 
has raised concerns about increased myocardial infarction (MI) risk among patients 
taking dabigatran but the US Food and Drug Administration (FDA) has not found 
an increase MI risk among patients taking dabigatran in its observational study 
[22]. Because dabigatran is highly renally cleared, the serum creatinine and creati-
nine clearance has to be regularly monitored.
3.5 Rivaroxaban
3.5.1 Mechanism of action
Rivaroxaban is the first direct factor Xa inhibitor [16]. It therefore prevents the 
formation of factor II to factor IIa. It acts one step higher on the coagulation cascade 
compared to dabigatran. Rivaroxaban is able to bind to both free and clot-bound 
factor Xa due to its small size (436 g/mol) [10].
3.5.2 ADME
Rivaroxaban has good bioavailability of 66% when taken without food. The 
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Rivaroxaban reaches its peak concentration about 2–4 hours after ingestion. 
Rivaroxaban is highly protein bound at 95%. Two-thirds of the drug is degraded 
by the liver via CYP3A4 and CYP3A5, and CYP2J2 to a lesser extent, half of 
which is then excreted renally and the other half is excreted by the hepato-
biliary route into the feces. The remaining one-third of the drug is excreted 
renally. Rivaroxaban is a P-gp substrate both at the gut and at the kidney, hence 
Table 2. 
Characteristics, efficacy, and safety data of warfarin vs. DOACs for stroke and systemic embolism prevention 
in patients with non-valvular atrial fibrillation. Adapted from [31] under Creative Commons (CC BY) 
Attribution 4.0 International License.
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drug–drug interaction between rivaroxaban and P-gp substrates, inhibitors, or 
inducers must be taken note of. The half-life of rivaroxaban is about 5–9 hours for 
the younger patients. It has a longer half-life of 11–13 hours among the elderly  
[15, 16] (see Table 1).
Table 3. 
Efficacy and safety data of DOACs venous thromboembolism treatment. Adapted from [18] under Creative 
Commons (CC BY) Attribution 4.0 International License.
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3.5.3 Clinical use
Rivaroxaban comes in various strengths of 2.5, 10, 15, and 20 mg tablets. It 
is approved for stroke and systemic embolism prevention in patients with non-
valvular AF, VTE treatment and prophylaxis including patients who had Total Knee 
Replacement (TKR) and Total Hip Replacement (THR), and for cardiovascular 
risk reduction among patients with Coronary Artery Disease (CAD) or Peripheral 
Artery Disease (PAD) in the United States.
For SSE prevention in patients with non-valvular AF, rivaroxaban has demon-
strated non-inferiority both in efficacy and safety compared to warfarin. Careful 
examination of the data from the Rivaroxaban versus Warfarin in Nonvalvular 
Atrial Fibrillation (ROCKET AF) trial shows that rivaroxaban has higher GI bleed-
ing rates but lower ICH rates compared to warfarin [23] (see Table 2).
For VTE treatment, rivaroxaban is non-inferior as well compared to warfarin (see 
Table 3). However, the initial treatment dose is 15 mg twice daily × 3 weeks followed 
by 20 mg daily [18]. The reason for the twice daily dosing is likely due to the need 
for a higher concentration for clot resolution and prevention of further propagation, 
knowing that the risk of VTE occurrence is highest during the first 3–4 weeks [24].
At a dose of 2.5 mg twice daily in combination with aspirin and either clopi-
dogrel or ticlopidine, rivaroxaban has shown small 16% relative risk reduction, or 
1.6% absolute risk reduction (NNT = 63) for death due to cardiovascular causes, 
MI, or stroke. This is at the backdrop of higher bleeding events (NNH = 83 for 
TIMI major bleeding events not associated with CABG) [25]. Patients subjected to 
rivaroxaban 2.5 mg twice daily need to be carefully selected.
3.5.4 Monitoring
No routine laboratory monitoring is needed for rivaroxaban for its pharmaco-
dynamic effect. Rivaroxaban may affect PT/INR depending on the reagent used; 
elevated PT/INR may signal the presence of the drug but rivaroxaban cannot be 
excluded even if the PT/INR is normal [15, 20, 21]. Rivaroxaban may affect aPTT 
but less so compared to PT/INR. The best test to measure for the effect of the drug 
is via anti-factor Xa assay [20, 21], which is not routinely available in most hospital 
laboratories. Patient’s serum creatinine and creatinine clearance should be periodi-
cally monitored to see if dose adjustment might be needed.
3.5.5 Adverse effects
Bleeding is the adverse effect of utmost concern among patients started on rivar-
oxaban. Patients with history of GI bleeding should select other oral anticoagulants 
besides rivaroxaban due to its higher GI bleed risk when studied against warfarin.
3.6 Apixaban
3.6.1 Mechanism of action
Similar to rivaroxaban, apixaban is also a direct factor Xa inhibitor [16, 26]. It 
thus inhibits one step higher on the coagulation cascade compared to dabigatran. It 
binds to both free and clot-bound factor Xa.
3.6.2 ADME
Apixaban has a bioavailability of 50% and is an active drug itself. It is also a 
substrate of P-gp. It reaches peak concentration 2–4 hours after ingestion. It is 
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highly protein bound as well at 87%. Apixaban is cleared both via renal and non-
renal pathway. Fifty percent of the drug is excreted into the feces unchanged, 27% is 
also excreted in the urine unchanged. The remaining (~25%) undergoes metabolism 
by CYP3A4 and by other minor CYP enzymes such as CYP1A2, 2J2, 2C8, 2C9, and 
2C19. It has a half-life of 9–14 hours [15, 16, 19, 26] (see Table 1).
3.6.3 Clinical use
Apixaban is approved in the US for SSE in patients with non-valvular AF, VTE 
treatment and prophylaxis, including patients’ post-TKR and post-THR, and for long-
term recurrent VTE prophylaxis. It comes in two strengths of 2.5 and 5 mg tablets.
In the Apixaban versus Warfarin in Patients with Atrial Fibrillation 
(ARISTOTLE) trial, apixaban demonstrated superiority over warfarin titrated to an 
INR of 2–3 with relative risk reduction of 21%, absolute risk reduction of 0.33% giv-
ing an NNT of 303. This statistically significant result is driven mainly by a decrease 
in hemorrhagic stroke rates. In terms of bleeding events, apixaban demonstrated 
31% less bleeding compared to warfarin, mainly driven by decrease in ICH and 
bleeding other than GI bleeding rates. Of note, apixaban has similar GI bleeding 
rates versus warfarin. Apixaban is used at a dose of 5 mg twice daily for SSE preven-
tion (see Table 2). The dose is reduced to 2.5 mg twice daily if two out of the three 
following criteria are met: weight of ≤60 kg, serum creatinine of >1.5 mg/dl, or age 
of ≥80 years old according to the drug label. It should be noted that patients with 
CrCl of <25 ml/min are not included in the trial and hence other countries do not 
allow use of apixaban in patients with CrCl of <25 ml/min [27]. However, in the US, 
apixaban can be used at a dose of 2.5 mg twice daily even in patients with end-stage 
renal disease, including patients on dialysis, based on pharmacokinetic modeling.
For the treatment of VTE, apixaban is non-inferior to warfarin but has lower 
bleeding episodes (see Table 3). Apixaban is started at a dose of 10 mg twice daily for 
7 days followed by 5 mg twice daily [19, 26]. Similarly, apixaban should be avoided in 
patients with CrCl of <25 ml/min as these patients were excluded in the trial.
3.6.4 Monitoring
Apixaban does not require any laboratory monitoring as well. PT/INR is even 
less sensitive to apixaban compared to rivaroxaban. Anti-factor Xa assay specifically 
calibrated to apixaban is a sensitive test that could detect the presence and could 
give the quantity of the drug present in the sample. However, anti-factor Xa assay 
for DOACs are not readily available in most hospital laboratories [20, 21, 26].
3.6.5 Adverse effects
Patients on apixaban need to watch for bleeding, though apixaban has a better 
safety profile than warfarin.
3.7 Edoxaban
3.7.1 Mechanism of action
Edoxaban is also a direct factor Xa inhibitor, like rivaroxaban and apixaban [16].
3.7.2 ADME
Edoxaban is 62% bioavailable and is a P-gp substrate as well. Peak concentration 
occurs 1–2 hours after ingestion of edoxaban. Edoxaban is cleared both renally and 
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non-renally in a 50-50 manner. Fifty percent of the drug is metabolized hepatically via 
hydrolysis. Only 4% of the drug is metabolized by CYP3A4. The remaining 50% of the 
drug is excreted renally. It has a half-life of 10–14 hours [15, 19, 28] (see Table 1).
3.7.3 Clinical use
Edoxaban is approved both for SSE prevention in patients with non-valvular 
AF and VTE treatment. In the Edoxaban versus Warfarin in Patients with Atrial 
Fibrillation (ENGAGE AF-TIMI 48) trial, edoxaban has shown to be non-inferior 
to warfarin for SSE prevention [28] (see Table 2). However, a separate analysis that 
was published shows that at CrCl of >95 ml/min, edoxaban is not as protective as 
warfarin against SSE. Patients with CrCl >95 ml/min have lower edoxaban concen-
tration likely due to higher clearance of the drug among those with CrCl of 95 ml/
min [29]. Hence, edoxaban is not approved by the US FDA for use among patients 
with CrCl of >95 ml/min. In terms of bleeding episodes, edoxaban has lesser bleed-
ing risk than warfarin. Edoxaban comes in 30 and 60 mg doses. The 30 mg dose is 
used if patients have CrCL of 30–50 ml/min, weighs ≤60 kg, or is on verapamil, 
quinidine, or dronedarone (medication that are strong P-gp inhibitors) [28].
For the treatment of VTE, edoxaban is non-inferior to warfarin in terms of 
efficacy and has a lesser bleeding occurrence (see Table 3). There is no FDA rec-
ommendation whether it should be avoided in patients with CrCl > 95 ml/min due 
to lack of studies. However, it would seem prudent to also do the same for patients 
with VTE [18].
3.7.4 Monitoring
Edoxaban does not require monitoring like other DOACs. Similar to rivaroxaban 
and apixaban, PT/INR has low sensitivity towards edoxaban’s pharmacodynamic 
effect and is therefore not a good laboratory test to check on the presence of the 
drug. Anti-factor Xa assay calibrated to edoxaban remains to be the most sensitive 
test for edoxaban so far [20, 21, 28].
3.7.5 Adverse effects
Edoxaban has demonstrated lesser bleeding risk compared to warfarin in the 
clinical phase III studies.
4. Conclusion
The use of anticoagulants requires holistic evaluation of the patient and careful 
balancing of the thrombotic and bleeding risks of the patient. Understanding the phar-
macology, pharmacodynamics, pharmacokinetics, and clinical evidence behind the 
use of these drugs will help the clinician in selecting the best therapy for the patient.
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